Dr Alexandre Mebazaa (Hospital Lariboisiere, Paris, FR) discusses circulating dipeptidyl peptidase-3 as a myocardial depressant.
1. Why did you conduct this study?
2. What is the study design and end points?
2. What were your findings?
2. How should this study influence clinical practice and further research in these patients?
Filmed on site at ESC 2019 by Radcliffe Cardiology
Videography: Mike Knight & Tom Green
Interviewer: Liam O'Neill